



**Department of Health**  
Heidi Hedberg, Commissioner  
Robert Lawrence, MD, MA, CMO  
  
3601 C Street, Suite 540  
Anchorage, Alaska 99503

**Division of Public Health**  
Lindsey Kato, MPH, Director  
  
<https://health.alaska.gov/dph/Epi>  
24 Hour Emergency (800) 478-0084  
Local (907) 269-8000

**Editors:**  
Joe McLaughlin, MD, MPH  
Louisa Castrodale, DVM, MPH  
  
**Bulletin No. 15**  
August 29, 2025

## Influenza Vaccines Available During the 2025–26 Season

### Vaccines Available

Influenza vaccine options available in the United States this season include Afluria®, Fluarix®, FluLaval®, Fluzone®, Flucelvax®, Fluzone High-Dose®, Fludac®, Flublok®, and FluMist®.<sup>1</sup> The Alaska Immunization Program will supply 5 trivalent influenza vaccines this season (Table). All flu vaccines will only be available in single dose formulations.<sup>2</sup> Multidose vials using thimerosal as a preservative will not be supplied by the Immunization Program. Recommendations and administration information are published in a separate *Bulletin*.<sup>3</sup>

### 2025-26 Influenza Vaccine Composition<sup>1</sup>

Egg-based influenza vaccines contain hemagglutinin (HA) derived from:

- A/Victoria/4897/2022 (H1N1) pdm09-like virus
- A/Croatia/10136RV/2023 (H3N2)-like virus
- B/Austria/1359417/2021 (B/Victoria lineage)-like virus

Cell culture-based and recombinant (ccIIV4 and RIV4) influenza vaccines contain HA derived from:

- A/Wisconsin/67/2022 (H1N1) pdm09-like virus
- A/District of Columbia/27/2023 (H3N2)-like virus
- B/Austria/1359417/2021 (B/Victoria lineage)-like virus

### Storage

All influenza vaccine should be stored at 36°–46°F (2°–8°C) and should not be frozen.<sup>1</sup> Additional storage and handling guidelines are available on the vaccine package inserts.<sup>4</sup>

### Inactivated Influenza Vaccines (IIV)

The IIV vaccines available this season are:

- Egg-based (IIV3): Afluria® MDV, Fluarix®, FluLaval®, and Fluzone® are licensed for persons aged ≥6 months.<sup>3</sup>
- Cell culture-based (ccIIV3): Flucelvax® is licensed for persons aged ≥6 months.

- Egg-based high dose (HD-IIV3): Fluzone High-Dose® is licensed for persons aged ≥65 years.
- Egg-based with MF59 adjuvant (aIIV3): Fludac® is licensed for persons aged ≥65 years.

### Recombinant Influenza Vaccine (RIV)

Flublok® (RIV3) contains recombinant HA produced in an insect cell line using genetic sequences from cell-derived influenza viruses. Flublok® (RIV3) may be used in persons aged ≥9 years.<sup>2</sup>

### Live-Attenuated Influenza Vaccine (LAIV)

FluMist® (LAIV3) contains live, attenuated viruses that only replicate efficiently at temperatures present in the nasal mucosa. If the recipient sneezes immediately after administration, the dose should not be repeated. FluMist® (LAIV3) is available for persons aged 2 through 49 years who are not pregnant. Self-administered FluMist® is not available in Alaska this season.

### References

1. FDA. Influenza Vaccine Composition for the 2025–2026 U.S. Influenza Season. Available: <https://www.fda.gov/vaccines-blood-biologics/influenza-vaccine-composition-2025-2026-us-influenza-season>
2. CDC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP — United States, 2025–26 Influenza Season. *MMWR* 2025;74(32);500–7. Available at: <https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a2.htm>
3. Alaska Epidemiology *Bulletin*. “Influenza Vaccine Recommendations and Administration for the 2025–26 Season”. No. 16, August 29, 2025. Available at: [https://epi.alaska.gov/bulletins/docs/b2025\\_16.pdf](https://epi.alaska.gov/bulletins/docs/b2025_16.pdf)
4. U.S. Food and Drug Administration, Vaccines, Blood, and Biologics: Manufacturer Package Inserts. Available at: <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states>

Table. Alaska Immunization Program-Supplied Influenza Vaccines

Trade Name	Manufacturer	Presentation	Age Indication	HA (IIVs / RIV3) or virus count (VAIV3) per dose	Route
Standard dose, egg-based (IIV3)					
Fluzone®	Sanofi Pasteur	0.5 mL PFS	≥6 months	15 µg/0.5 mL dose	IM
Standard dose, cell culture based (ccIIV3)					
Flucelvax®	Seqirus	0.5 mL PFS	≥6 months	15 µg/0.5 mL dose	IM
High dose, egg-based (HD-IIV3)					
Fluzone HD®	Sanofi Pasteur	0.5 mL PFS	≥65 years	60 µg/0.5 mL dose	IM
Standard dose, egg-based vaccine with MF59 adjuvant (aIIV3)					
Fludac®	Seqirus	0.5 mL PFS	≥65 years	15 µg/0.5 mL dose	IM
Egg based (LAIV3) Afluria					
FluMist®	AstraZeneca	0.2 mL PFIS	2–49 years	10 fluorescent focus units/0.2mL	NAS

**Abbreviations:** IIV = inactivated influenza vaccine; RIV = recombinant influenza vaccine; LAIV = live attenuated influenza vaccine; cc = prefix indicating cell culture-based vaccine; a = prefix indicating adjuvanted inactivated vaccine; numeric suffix = specifies number of HA antigens in the vaccine; IM = intramuscular; NAS = nasal; PFS = pre-filled syringe; PFIS = pre-filled intranasal spray